Skip to main content

Synthetic Peptides: The Future of Patient Management in Systemic Rheumatic Diseases?

Buy Article:

$63.00 plus tax (Refund Policy)


Since the first description of self-reactive antibodies in systemic autoimmune rheumatic diseases, many autoantigens have been identified as useful diagnostic biomarkers in clinical immunology. Among the autoantigens, double-stranded desoxoribonucleic acid (dsDNA), the Smith antigen (Sm), topoisomerase-I (topo-I), proliferating cell nuclear antigen (PCNA), and others were described as hallmark targets of systemic autoimmune diseases. The detection of the corresponding autoantibodies can be performed with a variety of immunoassays based on native antigens, recombinant proteins or synthetic peptides. As discussed in this review, synthetic peptides often represent highly accurate antigenic ligands for autoantibody assays that can be easily produced in high quality and quantity and with remarkable reproducibility. Furthermore, the use of peptides that focus on abrogation or neutralization of pathogenic autoantibodies provides a possible new therapeutic approach to the management of autoimmune disorders. There is an increasing number of interesting examples for the application of synthetic peptides in diagnostic approaches. Today's sophisticated epitope mapping methods will potentate the identification of further peptides that can be possibly used as specific targets in diagnostic and therapeutic approaches to improve the patients' treatment. This may lead to a new scientific research area with high impact on the development of diagnostic and therapeutic products, to the area of peptide engineering and “theranostics”.

Keywords: Peptide; SLE; Systemic rheumatic disease; autoantibody; dsDNA

Document Type: Research Article


Affiliations: Dr. Fooke Laboratorien GmbH,Mainstr.85, 41469 Neuss, Germany.

Publication date: November 1, 2007

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more